Evidence map›Paper›PMID 39894842›Full record

ArticleParasites & vectors2025

AxiWorm: a new tool using YOLOv5 to test antiparasitic drugs against Trichinella spiralis.

Javier Sánchez-Montejo, Miguel Marín, María Alejandra Villamizar-Monsalve, María Del Carmen Vieira, Belén Vicente, Rafael Peláez, Julio López-Abán, Antonio Muro

Abstract read
In one paragraph

Article in Parasites & vectors, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Evaluation of the Efficacy of Anthelmintic Drugs AgainstAntibiotics (Basel, Switzerland) · 2026
    Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Javier Sánchez-MontejoInfectious and Tropical Diseases Research Group (E-INTRO), Biomedical Research Institute of Salamanca-Research Centre for Tropical Diseases at the University of Salamanca (IBSAL-CIETUS), Faculty of Pharmacy, University of Salamanca, 37007, Salamanca, Spain.
Miguel MarínDepartment of Pharmaceutical Sciences, Biomedical Research Institute of Salamanca-Research Centre for Tropical Diseases at the University of Salamanca (IBSAL-CIETUS), Faculty of Pharmacy, University of Salamanca, 37007, Salamanca, Spain.
María Alejandra Villamizar-MonsalveInfectious and Tropical Diseases Research Group (E-INTRO), Biomedical Research Institute of Salamanca-Research Centre for Tropical Diseases at the University of Salamanca (IBSAL-CIETUS), Faculty of Pharmacy, University of Salamanca, 37007, Salamanca, Spain.
María Del Carmen VieiraInfectious and Tropical Diseases Research Group (E-INTRO), Biomedical Research Institute of Salamanca-Research Centre for Tropical Diseases at the University of Salamanca (IBSAL-CIETUS), Faculty of Pharmacy, University of Salamanca, 37007, Salamanca, Spain.
Belén VicenteInfectious and Tropical Diseases Research Group (E-INTRO), Biomedical Research Institute of Salamanca-Research Centre for Tropical Diseases at the University of Salamanca (IBSAL-CIETUS), Faculty of Pharmacy, University of Salamanca, 37007, Salamanca, Spain.
Rafael PeláezDepartment of Pharmaceutical Sciences, Biomedical Research Institute of Salamanca-Research Centre for Tropical Diseases at the University of Salamanca (IBSAL-CIETUS), Faculty of Pharmacy, University of Salamanca, 37007, Salamanca, Spain.
Julio López-AbánInfectious and Tropical Diseases Research Group (E-INTRO), Biomedical Research Institute of Salamanca-Research Centre for Tropical Diseases at the University of Salamanca (IBSAL-CIETUS), Faculty of Pharmacy, University of Salamanca, 37007, Salamanca, Spain. jlaban@usal.es.
Antonio MuroInfectious and Tropical Diseases Research Group (E-INTRO), Biomedical Research Institute of Salamanca-Research Centre for Tropical Diseases at the University of Salamanca (IBSAL-CIETUS), Faculty of Pharmacy, University of Salamanca, 37007, Salamanca, Spain.

Funding

Doctoral Fellowship Program of "Junta de Castilla y León" co-funded by "Fondo Social Europeo" EDU875/2021; EDU/601/2020; EDU/1868/2022Instituto de Salud Carlos III PI22/01721MCIN/AEI/ doi 10.13039/501100011033 co-founded by European Union PID2021-127471OB-I00MCIN/AEI/ doi 10.13039/501100011033 co-founded by the European Union PID2022-136462NB-I00
6 · The paper itself

Abstract

BACKGROUND-

objectiveTrichinella spiralis drug development and control need an objective high throughput system to assess first stage larvae (L1) viability. YOLOv5 is an image recognition tool easily trained to count muscular first stage larvae (L1) and recognize morphological differences. Here we developed a semi-automated system based on YOLOv5 to capture photographs of 96 well microplates and use them for L1 count and morphological damage evaluation after experimental drug treatments. MATERIAL AND

methodsMorphological properties were used to distinguish L1 from debris after pepsin muscle digestion and distinguish healthy (serpentine) or damaged (coiled) L1s after 72 h untreated or treated with albendazole or mebendazole cultures. An AxiDraw robotic arm with a smartphone was used to scan 96 well microplates and store photographs. Images of L1 were manually annotated, and augmented based on exposure, bounding, blur, noise, and mosaicism.

resultsA total of 1309 photographs were obtained that after L1 labeling and data augmentation gave 27478 images. The final dataset of 12571 healthy and 14907 affected L1s was used for training, testing, and validating in a ratio of 70/20/10 respectively. A correlation of 92% was found in a blinded comparison with bare-eye assessment by experienced technicians.

conclusionYOLOv5 is capable of accurately counting and distinguishing between healthy and affected L1s, thus improving the performance of the assessment of meat inspection and potential new drugs.

Indexed as

AnthelminticsAntiparasitic AgentsImage Processing, Computer-AssistedTrichinella spiralisAlbendazoleAnimalsLarvaMebendazolePhotographyTrichinellosisAlbendazoleAnthelminticsAntiparasitic AgentsMebendazoleAxiWormComputer visionDrug screeningTrichinella spiralisYOLOv5

Identifiers

PMID39894842
PMCPMC11789287

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.